{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:46:17Z","timestamp":1779252377449,"version":"3.51.4"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>In this study, we aimed to compare the role of <jats:sup>68<\/jats:sup>Ga-labeled FAP inhibitor (<jats:sup>68<\/jats:sup>Ga-FAPI)-04 PET\/computed tomography (CT) and <jats:sup>18<\/jats:sup>F-fluorodeoxyglucose (<jats:sup>18<\/jats:sup>F-FDG) PET\/CT in the evaluation of primary tumor and metastases in patients diagnosed with malignant mesothelioma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>Our prospective study included 21 patients with histopathological diagnosis of malignant mesothelioma who underwent both <jats:sup>68<\/jats:sup>Ga-FAPI-04 PET\/CT and <jats:sup>18<\/jats:sup>F-FDG PET\/CT imaging between April 2022 and September 2022. Maximum standardized uptake value (SUVmax), metabolic tumor volume, total lesion glycolysis, tumor-to-background ratio (TBR) and highest SUVpeak (HPeak) values and lesion numbers were calculated from primary and metastatic lesions on FDG and FAPI PET\/CT images. Findings obtained from FAPI and FDG PET\/CT were compared.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>More lesions were detected in <jats:sup>68<\/jats:sup>Ga-FAPI-04 PET\/CT compared to <jats:sup>18<\/jats:sup>F-FDG PET\/CT in primary tumor and lymph node metastases. Statistically significantly higher SUVmax and TBR values were found with FAPI PET\/CT (primary lesion SUVmax and TBR, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.001 and <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001, respectively; lymph node SUVmax and TBR, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.016 and <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.005, respectively). With FAPI PET\/CT, upstage was observed according to tumor-node-metastasis staging in a total of seven patients including three patients with pleural origin, three patients with peritoneal origin and one patient with pericardial origin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In addition to the stage change with <jats:sup>68<\/jats:sup>Ga-FAPI-04 PET\/CT in malignant mesothelioma patients, a statistically significant superiority was observed in SUVmax, TBR and volumetric parameters in primary tumors and metastases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mnm.0000000000001702","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T04:00:14Z","timestamp":1682654414000},"page":"631-639","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of the role of 18F-fluorodeoxyglucose PET\/computed tomography and 68Ga-labeled FAP inhibitor-04 PET\/CT in patients with malignant mesothelioma"],"prefix":"10.1097","volume":"44","author":[{"given":"Yunus","family":"G\u00fczel","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Saglik Bilimleri University Diyarbakir Gazi Yasargil Training and Research Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halil","family":"K\u00f6mek","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saglik Bilimleri University Diyarbakir Gazi Yasargil Training and Research Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Canan","family":"Can","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saglik Bilimleri University Diyarbakir Gazi Yasargil Training and Research Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130hsan","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saglik Bilimleri University Diyarbakir Gazi Yasargil Training and Research Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferat","family":"Kepenek","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saglik Bilimleri University Diyarbakir Gazi Yasargil Training and Research Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senar","family":"Ebin\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Saglik Bilimleri University Diyarbakir Gazi Yasargil Training and Research Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Perver","family":"B\u00fcy\u00fckdeniz","sequence":"additional","affiliation":[{"name":"Department of Radiology, Silvan Dr.Yusuf Azizo\u011flu Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cihan","family":"G\u00fcndo\u011fan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Saglik Bilimleri University Diyarbakir Gazi Yasargil Training and Research Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Oru\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"R1-20250807","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1378\/chest.08-2665","article-title":"Malignant pleural mesothelioma: an update on biomarkers and treatment.","volume":"136","author":"Ray","year":"2009","journal-title":"Chest"},{"key":"R2-20250807","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20250807","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective.","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"R4-20250807","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival.","volume":"8","author":"Beebe-Dimmer","year":"2016","journal-title":"Clin Epidemiol"},{"key":"R5-20250807","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma.","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"R6-20250807","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification.","volume":"17","author":"Sauter","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R7-20250807","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1148\/rg.346130089","article-title":"Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma.","volume":"34","author":"Nickell","year":"2014","journal-title":"Radiographics"},{"key":"R8-20250807","article-title":"Imaging of malignant pleural, pericardial, and peritoneal mesothelioma.","author":"Strange","year":"2022","journal-title":"Adv Anat Pathol"},{"key":"R9-20250807","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol"},{"key":"R10-20250807","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R11-20250807","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","article-title":"Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy.","volume":"8","author":"Hamson","year":"2014","journal-title":"Proteomics Clin Appl"},{"key":"R12-20250807","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer.","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"R13-20250807","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00259-020-04940-6","article-title":"Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in patients presenting with inconclusive [18F]FDG PET\/CT findings.","volume":"48","author":"Chen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R14-20250807","doi-asserted-by":"crossref","first-page":"543","DOI":"10.21037\/tlcr.2018.07.05","article-title":"The eighth TNM classification for malignant pleural mesothelioma.","volume":"7","author":"Berzenji","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"R15-20250807","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/cncr.25640","article-title":"A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*.","volume":"117","author":"Yan","year":"2011","journal-title":"Cancer"},{"key":"R16-20250807","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures.","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann Surg"},{"key":"R17-20250807","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/2326-6066.CIR-14-0002","article-title":"The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance.","volume":"2","author":"Fearon","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"R18-20250807","doi-asserted-by":"crossref","first-page":"e0116683","DOI":"10.1371\/journal.pone.0116683","article-title":"Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis.","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"R19-20250807","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer.","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R20-20250807","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1097\/RLU.0000000000003489","article-title":"Fibroblast activation protein inhibitor PET\/CT: a promising molecular imaging tool.","volume":"46","author":"Sharma","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R21-20250807","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3892\/or.2020.7669","article-title":"Connective tissue growth factor produced by cancer-associated fibroblasts correlates with poor prognosis in epithelioid malignant pleural mesothelioma.","volume":"44","author":"Ohara","year":"2020","journal-title":"Oncol Rep"},{"key":"R22-20250807","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein.","volume":"59","author":"Lindner","year":"2018","journal-title":"J Nucl Med"},{"key":"R23-20250807","doi-asserted-by":"crossref","first-page":"758958","DOI":"10.3389\/fonc.2021.758958","article-title":"Fibroblast-activated protein inhibitor PET\/CT: cancer diagnosis and management.","volume":"11","author":"Kuyumcu","year":"2021","journal-title":"Front Oncol"},{"key":"R24-20250807","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/RLU.0000000000004269","article-title":"68 Ga-FAPI-04 versus 18 F-FDG PET\/CT in detection of epithelioid malignant pleural mesothelioma.","volume":"47","author":"Dong","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R25-20250807","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1053\/j.semnuclmed.2022.04.008","article-title":"A role for PET\/CT in response assessment of malignant pleural mesothelioma.","volume":"52","author":"Sandach","year":"2022","journal-title":"Semin Nucl Med"},{"key":"R26-20250807","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00330-008-0918-9","article-title":"Therapy response in malignant pleural mesothelioma: role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT.","volume":"18","author":"Plathow","year":"2008","journal-title":"Eur Radiol"},{"key":"R27-20250807","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.107.042333","article-title":"Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.","volume":"48","author":"Francis","year":"2007","journal-title":"J Nucl Med"},{"key":"R28-20250807","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1158\/1078-0432.CCR-09-2313","article-title":"A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.","volume":"16","author":"Nowak","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R29-20250807","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00259-014-2960-y","article-title":"Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.","volume":"42","author":"Lopci","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R30-20250807","doi-asserted-by":"crossref","first-page":"16261","DOI":"10.1038\/s41598-022-20447-6","article-title":"[68Ga]FAPI-PET\/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas.","volume":"12","author":"Guberina","year":"2022","journal-title":"Sci Rep"},{"key":"R31-20250807","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40644-016-0091-3","article-title":"How we read oncologic FDG PET\/CT.","volume":"16","author":"Hofman","year":"2016","journal-title":"Cancer Imaging"},{"key":"R32-20250807","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1007\/s00259-018-4043-y","article-title":"Risk-related 18F-FDG PET\/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial.","volume":"45","author":"Spadafora","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R33-20250807","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/RCT.0000000000000174","article-title":"Use of computed tomography and positron emission tomography\/computed tomography for staging of local extent in patients with malignant pleural mesothelioma.","volume":"39","author":"Frauenfelder","year":"2015","journal-title":"J Comput Assist Tomogr"},{"key":"R34-20250807","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1148\/radiol.211424","article-title":"Comparison of 68Ga-FAPI and 18F-FDG PET\/CT in the evaluation of advanced lung cancer.","volume":"303","author":"Wang","year":"2022","journal-title":"Radiology"},{"key":"R35-20250807","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/MNM.0000000000001607","article-title":"Comparison of 18 F-FDG PET\/CT and 68 Ga-FAPI-04 PET\/CT in patients with non-small cell lung cancer.","volume":"43","author":"Can","year":"2022","journal-title":"Nucl Med Commun"},{"key":"R36-20250807","doi-asserted-by":"crossref","first-page":"1047010","DOI":"10.3389\/fonc.2022.1047010","article-title":"Prospective comparison of 68Ga-FAPI-04 and 18F-FDG PET\/CT for tumor staging in nasopharyngeal carcinoma.","volume":"12","author":"Ding","year":"2022","journal-title":"Front Oncol"},{"key":"R37-20250807","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s00330-022-09251-y","article-title":"Usefulness of [68Ga]FAPI-04 and [18F]FDG PET\/CT for the detection of primary tumour and metastatic lesions in gastrointestinal carcinoma: a comparative study.","volume":"33","author":"Li","year":"2023","journal-title":"Eur Radiol"},{"key":"R38-20250807","doi-asserted-by":"crossref","first-page":"9750080","DOI":"10.1155\/2021\/9750080","article-title":"FAPI-04 uptake in healthy tissues of cancer patients in 68Ga-FAPI-04 PET\/CT imaging.","volume":"2021","author":"G\u00fcndo\u011fan","year":"2021","journal-title":"Contrast Media Mol Imaging"},{"key":"R39-20250807","doi-asserted-by":"crossref","first-page":"978506","DOI":"10.3389\/fonc.2022.978506","article-title":"A systematic review of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET\/CT in the diagnostic value of malignant tumor bone metastasis.","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"R40-20250807","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","article-title":"Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer.","volume":"47","author":"Chen","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R41-20250807","doi-asserted-by":"crossref","first-page":"737827","DOI":"10.3389\/fonc.2021.737827","article-title":"Comparison of the relative diagnostic performance of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET\/CT for the detection of bone metastasis in patients with different cancers.","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"key":"R42-20250807","first-page":"S1015-9584(22)01572-X","article-title":"A case report of breast metastasis from malignant pleural mesothelioma invading the rhabdoid muscle.","author":"Kong","year":"2022","journal-title":"Asian J Surg"},{"key":"R43-20250807","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.18632\/oncotarget.27324","article-title":"Clinical utility of FDG-PET\/CT for post-surgery surveillance of malignant pleural mesothelioma \u2013 comparison with contrast-enhanced CT.","volume":"10","author":"Kitajima","year":"2019","journal-title":"Oncotarget"},{"key":"R44-20250807","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10120-011-0017-5","article-title":"Japanese Gastric Cancer Association Task Force for research promotion: clinical utility of \u00b98F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature.","volume":"14","author":"Shimada","year":"2011","journal-title":"Gastric Cancer"},{"key":"R45-20250807","first-page":"22","article-title":"Role of 18F-FDG PET\/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.","volume":"33","author":"Rubini","year":"2014","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"R46-20250807","doi-asserted-by":"crossref","first-page":"20170519","DOI":"10.1259\/bjr.20170519","article-title":"Diagnostic accuracy of 18F-FDG PET\/CT for detection of peritoneal carcinomatosis; a systematic review and meta-analysis.","volume":"91","author":"Kim","year":"2018","journal-title":"Br J Radiol"},{"key":"R47-20250807","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2214\/AJR.20.24302","article-title":"Will FAPI PET\/CT replace FDG PET\/CT in the next decade? point-an important diagnostic, phenotypic, and biomarker role.","volume":"216","author":"Calais","year":"2021","journal-title":"AJR Am J Roentgenol"},{"key":"R48-20250807","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1007\/s00259-020-05146-6","article-title":"Role of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET\/CT.","volume":"48","author":"Zhao","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R49-20250807","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/RLU.0b013e318299609f","article-title":"PET or PET\/CT for detection of peritoneal carcinomatosis: a meta-analysis.","volume":"38","author":"Chang","year":"2013","journal-title":"Clin Nucl Med"},{"key":"R50-20250807","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/RLU.0000000000003858","article-title":"68Ga-FAPI-04 PET\/CT versus 18F-FDG PET\/CT in malignant peritoneal mesothelioma.","volume":"47","author":"G\u00fcndo\u011fan","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R51-20250807","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jtho.2022.09.224","article-title":"Pericardial mesothelioma, a disease for brave hearts.","volume":"17","author":"Grosso","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R52-20250807","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/RLU.0b013e3182478c13","article-title":"A case of primary pericardial mesothelioma detected by 18F-FDG PET\/CT.","volume":"37","author":"Aga","year":"2012","journal-title":"Clin Nucl Med"},{"key":"R53-20250807","first-page":"1","article-title":"A rare case of distant metastasis of primary malign pericardial mesothelioma with 18F-FDG PET\/CT.","volume":"2","author":"Seng\u00f6z","year":"2019","journal-title":"J Clin Res Med"},{"key":"R54-20250807","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s13139-016-0425-x","article-title":"Unusual contiguous soft tissue spread of advanced malignant mesothelioma detected by FDG PET\/CT.","volume":"51","author":"Zhang","year":"2017","journal-title":"Nucl Med Mol Imaging"},{"key":"R55-20250807","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1007\/s00259-021-05255-w","article-title":"A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET\/MR in patients with nasopharyngeal carcinoma: a prospective study.","volume":"48","author":"Qin","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R56-20250807","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1007\/s00259-021-05336-w","article-title":"Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography\/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma.","volume":"48","author":"Zhao","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000001702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:04:45Z","timestamp":1754597085000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000001702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000001702","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,28]]}}}